Light-activated therapy for localized prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your prostate cancer was diagnosed within the last 9 months, is still inside the prostate, and has a Gleason score of 7 (3+4 or 4+3).
- Your PSA level is 15 or less, and the main tumor on MRI is smaller than 1.5 cubic centimeters.
- You have not had any prior prostate cancer treatment like surgery, radiation, hormone therapy, or chemotherapy.
- You are in good overall health (able to care for yourself) and your blood/kidney/liver tests are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
This trial tests a laser treatment that targets only the cancerous part of the prostate. It may be an option for men with intermediate-risk prostate cancer who do not want their entire prostate removed.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial tests whether using a special PSMA-PET scan to guide radiation therapy improves treatment for men with high-risk prostate cancer that hasn't spread. You would receive standard radiation plus hormone therapy, and the scan helps the doctor target the radiation more precisely.
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
This trial tests a new radiation approach for prostate cancer that has not spread. It combines different types of radiation with or without hormone therapy to see if this approach works better with fewer side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.